Mark Thomas Esper (born April 26, 1964)[1][2] i... - dofaq.co
Mark Thomas Esper (born April 26, 1964)[1][2] i...
wikipedia - 22 Dec 2020
Mark Thomas Esper (born April 26, 1964)[1][2] is a U.S. politician and businessman who served as the 27th United States secretary of defense from July 2019 to November 2020. He was a defense contractor lobbyist before joining the Donald Trump administration.
Can BioNTech, Up 26%, Ride Summit's Coattails To A Recovery?
Investor's Business Daily - 17 Sep 2024
Can BioNTech, Up 26%, Ride Summit's Coattails To A Recovery? ...
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
Yahoo Finance - 13 Sep 2024
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar? ...
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
StockTitan - 17 Sep 2024
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024 ...
Comparing the COVID-19 Vaccines: How Are They Different?
Yale Medicine - 03 Sep 2024
Comparing the COVID-19 Vaccines: How Are They Different? ...
Decoding BioNTech's Options Activity: What's the Big Picture?
Benzinga - 17 Sep 2024
Decoding BioNTech's Options Activity: What's the Big Picture? ...
BioNTech stock raised to buy at Jefferies (NASDAQ:BNTX)
Seeking Alpha - 17 Sep 2024
BioNTech stock raised to buy at Jefferies (NASDAQ:BNTX) ...
ESMO24: A cancer cachexia drug, VEGF enthusiasm and immunotherapy’s survival impact
BioPharma Dive - 16 Sep 2024
ESMO24: A cancer cachexia drug, VEGF enthusiasm and immunotherapy’s survival impact ...
BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth
Simply Wall St - 13 Sep 2024
BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth ...
ESMO 2024: Encouraging mid-stage results on BioNTech asset
The Pharma Letter - 17 Sep 2024
ESMO 2024: Encouraging mid-stage results on BioNTech asset ...
BioNTech SE ADR rises Monday, still underperforms market
MarketWatch - 16 Sep 2024
BioNTech SE ADR rises Monday, still underperforms market ...
Jefferies lifts BioNTech stock price target on new drug potential
Investing.com - 13 Sep 2024
Jefferies lifts BioNTech stock price target on new drug potential ...
BioNTech upgraded to Neutral from Underweight at JPMorgan
TipRanks - 16 Sep 2024
BioNTech upgraded to Neutral from Underweight at JPMorgan ...
GSK surrenders HSV vaccine hopes after phase 2 fail, ceding race to Moderna, BioNTech
Fierce Biotech - 11 Sep 2024
GSK surrenders HSV vaccine hopes after phase 2 fail, ceding race to Moderna, BioNTech ...
US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug
Reuters.com - 17 Jun 2024
US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug ...
Summit lifts Instil, BioNTech on Merck beating data (NASDAQ:SMMT)
Seeking Alpha - 13 Sep 2024
Summit lifts Instil, BioNTech on Merck beating data (NASDAQ:SMMT) ...
Market Whales and Their Recent Bets on BNTX Options
Benzinga - 13 Sep 2024
Market Whales and Their Recent Bets on BNTX Options ...
BioNTech SE ADR rises Friday, outperforms market
MarketWatch - 13 Sep 2024
BioNTech SE ADR rises Friday, outperforms market ...
BioNTech says 90% of 2024 revenues will accrue at end of year
Reuters.com - 06 May 2024
BioNTech says 90% of 2024 revenues will accrue at end of year ...
Forecasting The Future: 8 Analyst Projections For BioNTech
Benzinga - 13 Sep 2024
Forecasting The Future: 8 Analyst Projections For BioNTech ...